Evidence mapPaperPMID 18640587Full record

ReviewDiabetes & metabolism2008

Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.

R Lupi, S Del Prato

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetes & metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04131582 (Effect of a Quadruple Therapy on Pancreatic Islet Function, Insulin Resistance and Cardiovascular Function in Patients With Mixed Prediabetes and Obesity), which is not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04131582 phase3unknown statusstarted 2019, after this paper: background citation

Effect of a Quadruple Therapy on Pancreatic Islet Function, Insulin Resistance and Cardiovascular Function in Patients With Mixed Prediabetes and Obesity: Randomized Clinical Trial

Ran2019Enrolled34Registered outcomes4Posted comparisons0ConditionsInsulin Resistance, Prediabetic StateArmsLinagliptin + metformin and Empagliflozin + metformin, Metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. IRS-2/Akt/GSK-3Oxidative medicine and cellular longevity · 2021
    Article
  8. Article
  9. Article
  10. A novel polysaccharide fromFood & nutrition research · 2019
    Article
  11. Article
  12. Article
  13. Evidence-based complementary and alternative medicine : eCAM · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Targeting metabolic disorders by natural products.Journal of diabetes and metabolic disorders · 2015
    Article
  18. Systematic investigation into the role of intermittent high glucose in pancreatic beta-cells.International journal of clinical and experimental medicine · 2015
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

R LupiDepartment of Endocrinology and Metabolism, Section of Diabetes and Metabolic Diseases, University of Pise, Italy.
S Del Prato

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes, the most common form of diabetes in humans, is characterized by impaired insulin secretion paralleled by a progressive decline in beta-cell function and chronic insulin resistance. Several authors have showed that in type 2 diabetes there is a reduction of islet and/or insulin-containing cell mass or volume. Regulation of the beta-cell mass appears to involve a balance of beta-cell replication and apoptosis but, at the molecular level, pancreatic beta-cell loss by apoptosis appears to play an important role in the development of insulin deficiency and the onset and/or progression of the disease. The mechanisms favoring apoptosis in type 2 diabetic pancreatic islets and new potential therapeutic approaches to prevent beta-cell death and maintain beta-cell mass are discussed.

Indexed as

ApoptosisAdministration, OralAmyloidBlood GlucoseDiabetes Mellitus, Type 2HumansHypoglycemic AgentsInsulin-Secreting CellsIslet Amyloid PolypeptideSulfonylurea CompoundsAmyloidBlood GlucoseHypoglycemic AgentsIslet Amyloid PolypeptideSulfonylurea Compounds

Identifiers

PMID18640587
OpenAlexW1974325232

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.